(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are VerifyMe, SmileDirectClub, and W&T Offshore.

Rank Financial Asset Price Change Updated (EST)
1 VerifyMe (VRME) 1.59 11.97% 2022-09-15 14:53:12
2 SmileDirectClub (SDC) 1.25 11.62% 2022-09-15 14:55:19
3 W&T Offshore (WTI) 7.43 10.57% 2022-09-15 05:06:07
4 Tetra Technologies (TTI) 4.46 9.05% 2022-09-14 19:15:06
5 Humana (HUM) 498.16 8.57% 2022-09-15 14:50:31
6 Roku (ROKU) 73.70 7.83% 2022-09-15 14:55:16
7 Advaxis (ADXS) 2.92 6.96% 2022-09-15 10:41:16
8 Aehr Test Systems (AEHR) 17.66 6.77% 2022-09-15 10:42:15
9 Acorn Energy (ACFN) 0.50 6.68% 2022-09-15 07:42:16
10 Pacific Biosciences of California (PACB) 6.53 6.44% 2022-09-15 14:45:26

The three biggest losers today are Adobe, Catalyst Pharmaceuticals, and Groupon.

Rank Financial Asset Price Change Updated (EST)
1 Adobe (ADBE) 309.52 -16.69% 2022-09-15 14:54:54
2 Catalyst Pharmaceuticals (CPRX) 13.58 -12.5% 2022-09-15 14:56:47
3 Groupon (GRPN) 11.14 -10.78% 2022-09-15 14:43:19
4 TherapeuticsMD (TXMD) 7.79 -8.84% 2022-09-15 14:55:57
5 DAQO New Energy (DQ) 57.99 -7.42% 2022-09-15 14:48:31
6 West Pharmaceutical (WST) 274.45 -5.63% 2022-09-15 14:47:12
7 MongoDB (MDB) 233.40 -5.59% 2022-09-15 14:54:26
8 Ecopetrol S.A. (EC) 10.40 -5.58% 2022-09-15 14:59:26
9 Gevo (GEVO) 2.51 -5.47% 2022-09-15 14:43:04
10 Tronox Limited Ordinary Shares (TROX) 13.40 -5.3% 2022-09-14 19:09:06

Winners today

1. VerifyMe (VRME) – 11.97%

VerifyMe, Inc., is a provider of technology solutions that connects brands and consumers in the United States. VerifyMe engage services are offered by the company. This allows the brand owner the opportunity to collect business intelligence and interact with consumers using an authentication test. VerifyMe Engage services are also offered by the company. These include VerifyInk (a patent invisible ink); VerifyAuthenticator technology which is a mobile device with the VerifyMe App to decode and authenticate VerifyInk codes. VerifyLabel and VerifyChecker both handheld devices that can authenticate VerifyInk’s unique frequency. VerifyMe Track & Trace is a cloud-based tracking and authentication system that ties to VerifyCode. It also offers VerifyMe online, which includes technology and services to help customers combat counterfeit domains, e-commerce platforms and social media websites that promote or sell counterfeit products. INX International Ink Company has formed a strategic partnership between VerifyMe, Inc. and VerifyMe, Inc. The company used to be known as LaserLock Technologies, Inc., but changed its name in July 2015 to VerifyMe, Inc. VerifyMe, Inc. is an American company that was founded in 1999. Its headquarters are in Rochester, New York.

NASDAQ ended the session with VerifyMe jumping 11.97% to $1.59 on Thursday while NASDAQ fell 1.43% to $11,552.36.

Volume

Today’s last reported volume for VerifyMe is 21161 which is 91.41% below its average volume of 246527.

VerifyMe’s last close was $1.42, 66.82% below its 52-week high of $4.28.

VerifyMe’s Sales

VerifyMe’s sales growth is 2900% for the present quarter and 1666.7% for the next. The company’s growth estimates for the current quarter and the next is a negative 183.3% and a negative 108.4%, respectively.

VerifyMe’s Revenue

Year-on-year quarterly revenue growth declined by 14.4%, now sitting on 840k for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

VerifyMe’s stock is considered to be overbought (>=80).

VerifyMe’s Stock Yearly Top and Bottom Value

VerifyMe’s stock is valued at $1.59 at 17:32 EST, way below its 52-week high of $4.28 and way higher than its 52-week low of $1.17.

VerifyMe’s Moving Average

VerifyMe’s value is way below its 50-day moving average of $1.80 and way under its 200-day moving average of $2.78.

More news about VerifyMe.

2. SmileDirectClub (SDC) – 11.62%

SmileDirectClub, Inc., a dental care company, provides clear aligner therapy. It manages all aspects of the treatment process including marketing, manufacturing and fulfillment. The company also monitors patients through their progress through treatment. SmileCheck, Inc. has approximately 250 dentists in America, Canada, Australia and New Zealand. The company also sells aligners and impression and whitening kit, whitening gels and retainers. It also stocks toothbrushes and toothpastes as well as water flossers and SmileSpa and other ancillary products. It was established in Nashville, Tennessee in 2014.

NASDAQ ended the session with SmileDirectClub jumping 11.62% to $1.25 on Thursday, after five sequential sessions in a row of losses. NASDAQ slid 1.43% to $11,552.36, following the last session’s upward trend on what was an all-around down trend exchanging session today.

Volume

Today’s last reported volume for SmileDirectClub is 3466330 which is 20.85% below its average volume of 4379620.

SmileDirectClub’s last close was $1.12, 84.91% below its 52-week high of $7.42.

SmileDirectClub’s Revenue

Year-on-year quarterly revenue growth declined by 24%, now sitting on 589.8M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

SmileDirectClub’s stock is considered to be overbought (>=80).

SmileDirectClub’s Stock Yearly Top and Bottom Value

SmileDirectClub’s stock is valued at $1.25 at 17:32 EST, way below its 52-week high of $7.42 and way higher than its 52-week low of $0.98.

SmileDirectClub’s Moving Average

SmileDirectClub’s worth is below its 50-day moving average of $1.25 and way under its 200-day moving average of $1.91.

More news about SmileDirectClub.

3. W&T Offshore (WTI) – 10.57%

W&T Offshore, Inc. is an independent producer of natural and oil products. It focuses on the exploration, acquisition, and development of natural and oil properties in the Gulf of Mexico. It sells natural gas liquids and crude oil. The company has a working interest in 41 off-shore fields located in state and federal waters. The company has an interest in leases that cover approximately 669,000 net acres. These are located off the coasts Louisiana, Texas and Mississippi. Houston is the headquarters of this company, which was established in 1983.

NYSE ended the session with W&T Offshore rising 10.57% to $7.43 on Thursday while NYSE fell 0.82% to $14,722.03.

Volume

Today’s last reported volume for W&T Offshore is 6743380 which is 44.26% above its average volume of 4674140.

W&T Offshore’s last close was $7.43, 17.54% below its 52-week high of $9.01.

W&T Offshore’s Sales

W&T Offshore’s sales growth is 52.6% for the current quarter and 32.2% for the next.

W&T Offshore’s Revenue

Year-on-year quarterly revenue growth grew by 106.1%, now sitting on 754.27M for the twelve trailing months.

W&T Offshore’s Stock Yearly Top and Bottom Value

W&T Offshore’s stock is valued at $7.43 at 17:32 EST, way below its 52-week high of $9.01 and way above its 52-week low of $2.97.

W&T Offshore’s Moving Average

W&T Offshore’s value is way higher than its 50-day moving average of $5.40 and way above its 200-day moving average of $4.91.

More news about W&T Offshore.

4. Tetra Technologies (TTI) – 9.05%

TETRA Technologies Inc. and its subsidiaries operate as a diversified oil-and gas services company. Completion Fluids & Products and Water & Flowback Services are its two main segments. Clear brine fluids, chemicals, and other products are manufactured and sold by the Completion Fluids & Products division. They can be used in completion and well drilling operations throughout the United States as well as Europe, Asia and the Middle East. The segment sells both liquid and dried calcium chloride products. Water & Flowback Services provides services to water managers for oil and gas producers. The segment offers services such as frac flowback and production well testing. It also provides offshore cooling and related services for oil and gas operators in all of the major US and Mexican regions. The Woodlands is the headquarters of this company, which was founded in 1981.

NYSE ended the session with Tetra Technologies jumping 9.05% to $4.46 on Thursday while NYSE dropped 0.82% to $14,722.03.

Volume

Today’s last reported volume for Tetra Technologies is 1241320 which is 3.15% above its average volume of 1203310.

Tetra Technologies’s last close was $4.46, 23.37% under its 52-week high of $5.82.

Tetra Technologies’s Sales

Tetra Technologies’s sales growth is 28.5% for the present quarter and 27.4% for the next.

Tetra Technologies’s Revenue

Year-on-year quarterly revenue growth grew by 37.5%, now sitting on 479.38M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Tetra Technologies’s stock is considered to be oversold (<=20).

Tetra Technologies’s Stock Yearly Top and Bottom Value

Tetra Technologies’s stock is valued at $4.46 at 17:32 EST, way under its 52-week high of $5.82 and way above its 52-week low of $2.32.

Tetra Technologies’s Moving Average

Tetra Technologies’s value is way above its 50-day moving average of $3.97 and way above its 200-day moving average of $3.70.

More news about Tetra Technologies.

5. Humana (HUM) – 8.57%

Humana Inc. and its affiliates operate in the United States as a well-being and health company. The company operates in three main segments, namely, Retail, Group and Specialty and Healthcare Services. Individuals can get supplementary and medical benefits plans from the company. The company also has contracts with the Centers for Medicare & Medicaid Services for administering the Limited Income Newly eligible Transition prescription drug program. It also has agreements with several states for long-term support benefits, Medicaid eligibility, and dual eligible. The company also offers commercially fully insured specialty and medical insurance, including vision and dental care, along with administrative services to individual and group customers. It also offers home services services such as home healthcare and provider services as well as pharmacy solutions to members of its health plans and third-party customers. The company has approximately 17,000,000 members who are members of medical benefits plans and approximately 5 million specialty product members. Humana Inc. was established in 1961. It is located in Louisville, Kentucky.

NYSE ended the session with Humana jumping 8.57% to $498.16 on Thursday, after two consecutive sessions in a row of losses. NYSE dropped 0.82% to $14,722.03, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.

Humana shares rebound after positive profit guidance was raised and a long-term outlook offered.
Premarket trading on Thursday saw Humana Inc. share prices rebound 2.0% after hitting a low of three months in the prior session. The move was prompted by the company’s full-year profit outlook.

Volume

Today’s last reported volume for Humana is 2402210 which is 196.15% above its average volume of 811132.

Humana’s last close was $458.85, 9.14% under its 52-week high of $504.99.

Humana’s Sales

Humana’s sales growth is 9.5% for the current quarter and 7.2% for the next. The company’s growth estimates for the current quarter and the next is 30% and 80.6%, respectively.

Humana’s Revenue

Year-on-year quarterly revenue growth grew by 14.6%, now sitting on 90.51B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Humana’s stock is considered to be overbought (>=80).

Humana’s Stock Yearly Top and Bottom Value

Humana’s stock is valued at $498.16 at 17:33 EST, below its 52-week high of $504.99 and way above its 52-week low of $351.20.

Humana’s Moving Average

Humana’s value is above its 50-day moving average of $485.47 and way above its 200-day moving average of $447.02.

More news about Humana.

6. Roku (ROKU) – 7.83%

Roku, Inc., along with its affiliates, operate a streaming TV platform. It operates under two distinct segments: Platform and Player. The company’s platform allows people to search for and find TV shows and movies, live TV and news sports and many other entertainment options. The company has 60.1 million accounts as of December 31, 2021. The company also offers digital and video advertising and content distribution, subscription and billing services as well as brand sponsorship and promotions. It manufactures, licenses and sells smart TVs and TVs under its Roku TV trademark. The company also offers audio and streaming products, as well as accessories and brand buttons for remote control of streaming devices. The company sells its products through distributors and retailers as well as direct to consumers through its website. It is available in North America, Canada, Mexico, Brazil and Chile as well as through the United Kingdom and France. Roku, Inc., was founded in 2002. Its headquarters are in San Jose, California.

NASDAQ ended the session with Roku jumping 7.83% to $73.70 on Thursday, after two sequential sessions in a row of gains. NASDAQ slid 1.43% to $11,552.36, following the last session’s upward trend on what was an all-around down trend exchanging session today.

Volume

Today’s last reported volume for Roku is 17566600 which is 81.26% above its average volume of 9691260.

Roku’s last close was $68.35, 80.5% below its 52-week high of $350.60.

The company’s growth estimates for the current quarter and the next is a negative 222.9% and a negative 235.3%, respectively.

Roku’s Revenue

Year-on-year quarterly revenue growth grew by 18.5%, now sitting on 3.04B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Roku’s stock is considered to be overbought (>=80).

Roku’s Stock Yearly Top and Bottom Value

Roku’s stock is valued at $73.70 at 17:33 EST, way below its 52-week high of $350.60 and way higher than its 52-week low of $62.00.

Roku’s Moving Average

Roku’s value is under its 50-day moving average of $79.62 and way below its 200-day moving average of $125.49.

More news about Roku.

7. Advaxis (ADXS) – 6.96%

Advaxis, Inc. is a biotechnology company at the clinical stage. It focuses on developing and marketing proprietary Listeria monocytogenes technology antigen delivery product in the United States. ADXS-503 is currently in Phase 2 clinical trial for treatment of metastatic cancer. ADXS-503 is also in Phase 1/2 clinical studies for treatment of non-small-cell lung cancer. ADXS-504 is for prostate cancer treatment. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. Merck & Co., Inc., OS Therapies, LLC, Aratana Therapeutics Inc., Biocon Limited, Global BioPharma Inc., Knight Therapeutics Inc., and other companies have formed partnerships and collaborations. Advaxis, Inc., was established in Monmouth Junction, New Jersey in 2002.

NASDAQ ended the session with Advaxis jumping 6.96% to $2.92 on Thursday while NASDAQ fell 1.43% to $11,552.36.

Volume

Today’s last reported volume for Advaxis is 314 which is 92.62% below its average volume of 4255.

Advaxis’s last close was $2.73, 93.91% under its 52-week high of $44.80.

Advaxis’s Revenue

Year-on-year quarterly revenue growth declined by 81.8%, now sitting on 500k for the twelve trailing months.

Advaxis’s Stock Yearly Top and Bottom Value

Advaxis’s stock is valued at $2.92 at 17:33 EST, way below its 52-week high of $44.80 and way above its 52-week low of $2.00.

Advaxis’s Moving Average

Advaxis’s worth is way below its 50-day moving average of $3.66 and way under its 200-day moving average of $7.77.

More news about Advaxis.

8. Aehr Test Systems (AEHR) – 6.77%

Aehr Test Systems designs, engineers and manufactures semiconductor test and burnin equipment. The company offers complete wafer contact testing systems as well as test-while-burning systems and test fixtures. Advanced Burn-in and Test System is a family of test and packaged part burn-in systems that perform complex device test, including digital signal processors and microcontrollers. The company also offers FOX systems, which are parallel test-and-burn-in systems for devices that contact on wafers simultaneously. It also has a WaferPak contactor with a full wafer probe card that can be used in testing wafers within FOX system. DiePak carrier is a reusable temporary packaging that allows integrated circuit (ICs) manufacturers to test and burn in single- or multi-IC module modules. Test fixtures hold and connect devices that are under test. WaferPak Aligner is used to align the wafer of the customer to the WaferPak contactor. DiePak Loader automates loading the modules of customers to the DiePak carrier. Aehr Test Systems also offers customer support and programs including installation of systems, repairs, software engineering support, spare part inventory, training for customers, and documentation. Through a network distributors and representatives, the company sells its products directly to electronics manufacturers and contract assemblers. Aehr Test Systems, which was founded in 1977, is located in Fremont in California.

NASDAQ ended the session with Aehr Test Systems jumping 6.77% to $17.66 on Thursday, after two successive sessions in a row of gains. NASDAQ dropped 1.43% to $11,552.36, following the last session’s upward trend on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for Aehr Test Systems is 839597 which is 22.97% below its average volume of 1090040.

Aehr Test Systems’s last close was $16.54, 38.94% under its 52-week high of $27.09.

The company’s growth estimates for the current quarter and the next is 150% and 100%, respectively.

Aehr Test Systems’s Revenue

Year-on-year quarterly revenue growth grew by 165.6%, now sitting on 50.83M for the twelve trailing months.

Aehr Test Systems’s Stock Yearly Top and Bottom Value

Aehr Test Systems’s stock is valued at $17.66 at 17:33 EST, way under its 52-week high of $27.09 and way above its 52-week low of $6.71.

Aehr Test Systems’s Moving Average

Aehr Test Systems’s worth is way higher than its 50-day moving average of $13.42 and way above its 200-day moving average of $12.10.

More news about Aehr Test Systems.

9. Acorn Energy (ACFN) – 6.68%

Through its subsidiaries, Acorn Energy, Inc. develops and markets wireless remote control and monitoring systems for several markets throughout the United States as well internationally. The company operates in two distinct segments: Power Generation Monitoring (PG) and Cathodic Protect (CP) Monitoring. The PG segment offers wireless remote control and monitoring systems and services for crucial assets such as stand-by generators and compressors. The CP segment provides remote monitoring and control of the cathodic protection system on pipelines used by gas utilities as well as pipeline companies. This company was founded in 1986. It is located in Wilmington, Delaware.

NASDAQ ended the session with Acorn Energy rising 6.68% to $0.50 on Thursday while NASDAQ slid 1.43% to $11,552.36.

Volume

Today’s last reported volume for Acorn Energy is 100 which is 99.42% below its average volume of 17422.

Acorn Energy’s last close was $0.50, 28.57% under its 52-week high of $0.70.

Acorn Energy’s Revenue

Year-on-year quarterly revenue growth grew by 2.7%, now sitting on 6.82M for the twelve trailing months.

Acorn Energy’s Stock Yearly Top and Bottom Value

Acorn Energy’s stock is valued at $0.50 at 17:33 EST, way under its 52-week high of $0.70 and way above its 52-week low of $0.26.

Acorn Energy’s Moving Average

Acorn Energy’s worth is below its 50-day moving average of $0.51 and under its 200-day moving average of $0.53.

More news about Acorn Energy.

10. Pacific Biosciences of California (PACB) – 6.44%

Pacific Biosciences of California, Inc. develops, manufactures, and markets sequencing systems for complex genetic problems. PacBio’s Systems are used to monitor and analyze biochemical sequence reactions. The company also offers consumables such as single molecule real time (SMRT), cells and various reagent kit designs for specific workflows. For example, the template preparation kit is used to convert DNA into SMRTbell double stranded library formats. This includes molecular biology reagents such as ligase and buffers. The company also sells binding kits such as the modified DNA polymerase, which is used to bind SMRTbell library to the polymerase to prepare for sequencing. Sequencing kits include reagents that are required to perform on-instrument real-time sequencing including the phospholinked nuclear nucleotides. It serves commercial labs; research centers; genome centres; hospitals, public health laboratories, clinical research institutes, contract researchers organizations, academic institutions, pharmaceutical companies, and agricultural businesses. The company markets its products via a direct sales force throughout North America and Europe as well as distribution partners across Asia, Europe and the Middle East. Invitae Corporation has signed a partnership agreement for Pacific Biosciences of California, Inc.’s development and commercialization. Invitae Corporation was the company’s former name. The company became Pacific Biosciences of California, Inc., in 2005. Pacific Biosciences of California, Inc., was founded in 2000. It is located in Menlo Park, California.

NASDAQ ended the session with Pacific Biosciences of California rising 6.44% to $6.53 on Thursday while NASDAQ slid 1.43% to $11,552.36.

Volume

Today’s last reported volume for Pacific Biosciences of California is 7482240 which is 6.51% below its average volume of 8003740.

Pacific Biosciences of California’s last close was $6.13, 80.29% under its 52-week high of $31.10.

Pacific Biosciences of California’s Sales

Pacific Biosciences of California’s sales growth is 16.6% for the present quarter and 27.6% for the next. The company’s growth estimates for the present quarter and the next is a negative 52.4% and a negative 500%, respectively.

Pacific Biosciences of California’s Revenue

Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 134.69M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be overbought (>=80).

Pacific Biosciences of California’s Stock Yearly Top and Bottom Value

Pacific Biosciences of California’s stock is valued at $6.53 at 17:33 EST, way under its 52-week high of $31.10 and way above its 52-week low of $3.85.

Pacific Biosciences of California’s Moving Average

Pacific Biosciences of California’s worth is way higher than its 50-day moving average of $5.68 and way below its 200-day moving average of $9.74.

More news about Pacific Biosciences of California.

Losers Today

1. Adobe (ADBE) – -16.69%

Adobe Inc. is a global software company that offers a variety of services. The company operates in three areas: Digital Media and Digital Experience. Publishing and Advertising are its other segments. Digital Media offers solutions, products and services that allow individuals, groups, and companies to publish, promote, create and distribute content. Document Cloud is a cloud-based unified document service platform. Creative Cloud is its flagship product. It offers members access to all of the company’s creative products through a subscription. This segment is for content creators and workers as well as educators, students, journalists, bloggers, communicators, consumers, and marketers. Digital Experience provides a platform that integrates a number of services and applications. It enables brands to manage, optimize, measure and monetize customer experiences, from analytics to commerce. Marketers, marketers, retailers, agents, publishers, merchants and web analysts as well as data scientists, researchers, developers, and other executives in the C-suite. Publishing and Advertising offers products and services such as web conferencing and document and form platform, e-learning, publishing solutions and technical document publishing. It offers products and services to enterprises through local sales offices and its sales team. End users can also access its apps and website at Adobe.com. The company distributes its products and services via a network that includes value-added resellers and system integrators as well as retailers and original equipment producers. Adobe Systems Incorporated was the company’s former name. In October 2018, Adobe Inc. became Adobe Inc. Adobe Inc. was established in 1982. It is located in San Jose, California.

NASDAQ ended the session with Adobe falling 16.69% to $309.52 on Thursday, following the last session’s upward trend. NASDAQ slid 1.43% to $11,552.36, following the last session’s upward trend on what was an all-around bearish trend exchanging session today.

Adobe shares fall after WSJ reports that talks are underway to purchase figma in cash and stock for $20 billion
Adobe Inc. shares plunged 3.8% during premarket trades Thursday after having lost 17.2%.

Adobe stock (adbe) could fall to the level of 368?
Adobe Inc.’s stock trades on the Nasdaq under the ticker ADBE. Today, Adobe will announce its quarterly earnings. If the market has positive expectations, we may see the stock rising to its resistance at $385 or testing its support at $368.

Volume

Today’s last reported volume for Adobe is 25962400 which is 889.76% above its average volume of 2623100.

Adobe’s last close was $371.52, 46.89% below its 52-week high of $699.54.

The company’s growth estimates for the ongoing quarter and the next is 7.1% and 7.8%, respectively.

Adobe’s Revenue

Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 16.69B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Adobe’s stock is considered to be overbought (>=80).

Adobe’s Stock Yearly Top and Bottom Value

Adobe’s stock is valued at $309.52 at 17:34 EST, below its 52-week low of $338.00.

Adobe’s Moving Average

Adobe’s worth is way under its 50-day moving average of $400.06 and way under its 200-day moving average of $456.65.

Previous days news about Adobe

  • Adobe stock gets another downgrade. According to MarketWatch on Tuesday, 13 September, "BMO Capital Markets analyst Keith Bachman downgraded Adobe Systems Inc. shares to market perform from outperform Tuesday, though he noted that his ratings change reflected the results of a broader survey on interest in the company’s Creative Cloud suite of software rather than specific concerns about the upcoming quarterly results Adobe is due to report Thursday. ", "In short, respondents across the board expressed a greater willingness to move away from Adobe Creative Cloud in our August survey compared to our April survey," Bachman wrote. "

More news about Adobe.

2. Catalyst Pharmaceuticals (CPRX) – -12.5%

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical firm at the commercial stage. It focuses its efforts on commercializing treatments for neurological and rare neuromuscular diseases. Firdapse is an amifampridine-phosphate tablet for patients suffering from lambert–eaton syndrome (LEMS). Ruzurgi can be used to treat LEMS children. Firdapse is also developed by the company to treat MuSK antibody positive myasthenia Gravis and spinal muscular atrophy Type 3. It can also be used to treat hereditary nervepathy with liability for pressure palsies. Endo Ventures Limited and BioMarin Pharmaceutical Inc. have license agreements. Endo Ventures Limited has a collaboration agreement for the commercialization and development of generic Sabril tablets. Catalyst Pharmaceutical Partners, Inc. was the company’s former name. It changed its name in May 2015 to Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc., was established in 2002. It is located in Coral Gables, Florida.

NASDAQ ended the session with Catalyst Pharmaceuticals dropping 12.5% to $13.58 on Thursday, after three sequential sessions in a row of gains. NASDAQ slid 1.43% to $11,552.36, following the last session’s upward trend on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for Catalyst Pharmaceuticals is 8465730 which is 188.07% above its average volume of 2938740.

Catalyst Pharmaceuticals’s last close was $15.52, 0.58% under its 52-week high of $15.61.

Catalyst Pharmaceuticals’s Sales

Catalyst Pharmaceuticals’s sales growth is 56.2% for the current quarter and 54.1% for the next. The company’s growth estimates for the present quarter and the next is 54.5% and 80%, respectively.

Catalyst Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 42.7%, now sitting on 153.72M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Catalyst Pharmaceuticals’s stock is considered to be oversold (<=20).

Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value

Catalyst Pharmaceuticals’s stock is valued at $13.58 at 17:34 EST, way under its 52-week high of $15.61 and way higher than its 52-week low of $4.81.

Catalyst Pharmaceuticals’s Moving Average

Catalyst Pharmaceuticals’s value is way above its 50-day moving average of $11.35 and way above its 200-day moving average of $8.20.

More news about Catalyst Pharmaceuticals.

3. Groupon (GRPN) – -10.78%

Groupon, Inc., along with its affiliates, manages a marketplace which connects merchants and consumers. The company operates in North America as well as International. It sells products or services for third-party merchants and first-party inventory. The company serves its customers via mobile apps and web sites. The original name of the company was ThePoint.com, Inc., but it changed its name in October 2008 to Groupon, Inc. Groupon, Inc. was founded in 2008, and has its headquarters in Chicago, Illinois.

NASDAQ ended the session with Groupon falling 10.78% to $11.14 on Thursday, after four sequential sessions in a row of gains. NASDAQ slid 1.43% to $11,552.36, following the last session’s upward trend on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for Groupon is 1119660 which is 30.88% above its average volume of 855474.

Groupon’s last close was $12.48, 59.94% under its 52-week high of $31.15.

Groupon’s Sales

Groupon’s sales growth is a negative 40.8% for the current quarter and a decline by 19% for the next. The company’s growth estimates for the current quarter and the next is a negative 233.3% and a negative 28.9%, respectively.

Groupon’s Revenue

Year-on-year quarterly revenue growth declined by 41.9%, now sitting on 856.61M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Groupon’s stock is considered to be oversold (<=20).

Groupon’s Stock Yearly Top and Bottom Value

Groupon’s stock is valued at $11.14 at 17:34 EST, way under its 52-week high of $31.15 and way higher than its 52-week low of $8.78.

Groupon’s Moving Average

Groupon’s worth is higher than its 50-day moving average of $11.11 and way below its 200-day moving average of $17.75.

More news about Groupon.

4. TherapeuticsMD (TXMD) – -8.84%

TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17ss -estradiol, and progesterone to treat moderate-to–severe vasomotor conditions. TX-015HR is a transdermal progesterone cream. TX-006HR is an estradiol-progesterone cream. TX-017HR and TX-018HR are candidates for transdermal patches. TX-019HR is an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins, under the vitaTrue and vitaMedMD brands. It sells prescription drugs and prenatal vitamins to retail pharmacie distributors as well wholesale distributors. TherapeuticsMD, Inc., was established in Boca Raton, Florida in 2008.

NASDAQ ended the session with TherapeuticsMD falling 8.84% to $7.79 on Thursday while NASDAQ slid 1.43% to $11,552.36.

Volume

Today’s last reported volume for TherapeuticsMD is 85546 which is 87.97% below its average volume of 711125.

TherapeuticsMD’s last close was $8.55, 79.15% under its 52-week high of $41.00.

TherapeuticsMD’s Sales

TherapeuticsMD’s sales growth is 8.6% for the present quarter and 3.6% for the next. The company’s growth estimates for the present quarter and the next is 44.7% and 89.6%, respectively.

TherapeuticsMD’s Revenue

Year-on-year quarterly revenue growth declined by 2.7%, now sitting on 86.42M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TherapeuticsMD’s stock is considered to be overbought (>=80).

TherapeuticsMD’s Stock Yearly Top and Bottom Value

TherapeuticsMD’s stock is valued at $7.79 at 17:34 EST, way below its 52-week high of $41.00 and way above its 52-week low of $1.99.

TherapeuticsMD’s Moving Average

TherapeuticsMD’s value is under its 50-day moving average of $8.39 and way below its 200-day moving average of $12.88.

More news about TherapeuticsMD.

5. DAQO New Energy (DQ) – -7.42%

Daqo New Energy Corp. and its subsidiaries manufactures and distributes photovoltaic products manufactured from polysilicon in China. These products can be used to make solar power modules, ingots and wafers. Mega Stand International Limited was the company’s previous name. In August 2009, Daqo New Energy Corp. took over that title. Daqo New Energy Corp. is located in Shanghai in the People’s Republic of China.

NYSE ended the session with DAQO New Energy falling 7.42% to $57.99 on Thursday, following the last session’s upward trend. NYSE slid 0.82% to $14,722.03, following the last session’s upward trend on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for DAQO New Energy is 1794690 which is 1.78% above its average volume of 1763180.

DAQO New Energy’s Sales

DAQO New Energy’s sales growth is 160.3% for the ongoing quarter and 47% for the next. The company’s growth estimates for the current quarter and the next is 102.3% and 50.3%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

DAQO New Energy’s stock is considered to be overbought (>=80).

More news about DAQO New Energy.

6. West Pharmaceutical (WST) – -5.63%

West Pharmaceutical Services, Inc. manufactures, sells, and designs containment and delivery system for injectable medicines and other healthcare products. It is located in Americas, Europe, Middle East, Africa, Asia Pacific, Middle East, Africa, Asia Pacific, and Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. It offers stoppers for injectable packaging systems, syringe components and contract-manufactured products. Crystal Zenith is a cyclic-olefin-polymer that can be used to make drug containment products. It comes in vials and syringes as cartridges and self-injection device. The segment is available to pharmaceutical, generic and biologic drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This company serves medical, diagnostic and pharmaceutical companies. It distributes products via its distribution network and sales team, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc., was founded in 1923. It is located in Exton, Pennsylvania.

NYSE ended the session with West Pharmaceutical dropping 5.63% to $274.45 on Thursday while NYSE fell 0.82% to $14,722.03.

Volume

Today’s last reported volume for West Pharmaceutical is 626601 which is 66.54% above its average volume of 376237.

West Pharmaceutical’s last close was $290.82, 38.77% below its 52-week high of $475.00.

West Pharmaceutical’s Sales

West Pharmaceutical’s sales growth is 5.5% for the current quarter and 5.8% for the next. The company’s growth estimates for the ongoing quarter and the next is 12.1% and 22.1%, respectively.

West Pharmaceutical’s Revenue

Year-on-year quarterly revenue growth grew by 6.6%, now sitting on 2.93B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

West Pharmaceutical’s stock is considered to be overbought (>=80).

West Pharmaceutical’s Stock Yearly Top and Bottom Value

West Pharmaceutical’s stock is valued at $274.45 at 17:34 EST, under its 52-week low of $275.89.

West Pharmaceutical’s Moving Average

West Pharmaceutical’s value is way below its 50-day moving average of $316.26 and way under its 200-day moving average of $359.75.

More news about West Pharmaceutical.

7. MongoDB (MDB) – -5.59%

MongoDB, Inc. provides general purpose database platform worldwide. The company offers MongoDB Enterprise Advanced, a commercial database server for enterprise customers to run in the cloud, on-premise, or in a hybrid environment; MongoDB Atlas, a hosted multi-cloud database-as-a-service solution; and Community Server, a free-to-download version of its database, which includes the functionality that developers need to get started with MongoDB. The company also offers professional services, including consulting and training. MongoDB, Inc. was previously known as 10gen, Inc. MongoDB Inc. was founded in 2007. It is located in New York.

NASDAQ ended the session with MongoDB dropping 5.59% to $233.40 on Thursday while NASDAQ dropped 1.43% to $11,552.36.

Volume

Today’s last reported volume for MongoDB is 2645110 which is 66.6% above its average volume of 1587630.

MongoDB’s last close was $247.22, 58.1% below its 52-week high of $590.00.

The company’s growth estimates for the ongoing quarter and the next is a negative 16.7% and a negative 27.3%, respectively.

MongoDB’s Revenue

Year-on-year quarterly revenue growth grew by 57.1%, now sitting on 977.58M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

MongoDB’s stock is considered to be overbought (>=80).

MongoDB’s Stock Yearly Top and Bottom Value

MongoDB’s stock is valued at $233.40 at 17:34 EST, way under its 52-week high of $590.00 and higher than its 52-week low of $213.39.

MongoDB’s Moving Average

MongoDB’s value is way below its 50-day moving average of $313.69 and way below its 200-day moving average of $363.83.

More news about MongoDB.

8. Ecopetrol S.A. (EC) – -5.58%

Ecopetrol S.A. is an integrated energy company. Exploration and Production, Transport and Logistics, Refining and Petrochemical and Biofuels and Electric Power Transmission and Concessions are the four main segments of Ecopetrol S.A. The company is involved in exploration, production, transportation, of crude oil, engine fuels and fuel oil, as well as the sale and distribution of LPG and natural gas. It also provides electric power transmission services, design, development construction, operation and maintenance of roads and energy infrastructure projects. The company owned approximately 9.127 km of crude oil pipelines and multi-purpose pipes as of December 31, 2021. The company also makes and sells polypropylene compounds and masterbatches. It offers industrial services sales to customers as well as specialized management service. The company has offices in Colombia, Americas, Asia, Central America, the Caribbean, Europe and South America. Empresa Colombiana de Petroleos was the company’s previous name. Ecopetrol S.A. took over its operations in June 2003. Ecopetrol S.A. is an entity that was founded in Bogota (Colombia) in 1948.

NYSE ended the session with Ecopetrol S.A. falling 5.58% to $10.40 on Thursday, after two sequential sessions in a row of gains. NYSE dropped 0.82% to $14,722.03, following the last session’s upward trend on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Ecopetrol S.A. is 1221710 which is 24.22% below its average volume of 1612210.

Ecopetrol S.A.’s last close was $11.02, 44.37% under its 52-week high of $19.81.

Ecopetrol S.A.’s Sales

Ecopetrol S.A.’s sales growth is 71.8% for the current quarter and 59.4% for the next. The company’s growth estimates for the present quarter and the next is 109.5% and 106.1%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Ecopetrol S.A.’s stock is considered to be overbought (>=80).

Ecopetrol S.A.’s Stock Yearly Top and Bottom Value

Ecopetrol S.A.’s stock is valued at $10.40 at 17:34 EST, way under its 52-week high of $19.81 and way higher than its 52-week low of $9.31.

Ecopetrol S.A.’s Moving Average

Ecopetrol S.A.’s worth is below its 50-day moving average of $10.42 and way below its 200-day moving average of $14.16.

More news about Ecopetrol S.A..

9. Gevo (GEVO) – -5.47%

Gevo, Inc. is a company that produces renewable fuels. The company operates in four segments, Gevo, Agri-Energy and Renewable Natural Gas. It sells jet fuel and gasoline to reduce carbon emissions and greenhouse gas emissions. The company’s products include isooctane and isobutanol as well as renewable gasoline, diesel, and isobutanol. It also offers sustainable aviation fuel, natural gas, isobutylene and ethanol. Gevo, Inc. is a partner in ethanol-tojet technology development and commercial projects for sustainable aviation fuel. The company used to be known as Methanotech, Inc., but changed its name in March 2006 to Gevo, Inc. Gevo, Inc. was founded in 2005. It is located in Englewood, Colorado.

NASDAQ ended the session with Gevo falling 5.47% to $2.51 on Thursday while NASDAQ fell 1.43% to $11,552.36.

Volume

Today’s last reported volume for Gevo is 10490800 which is 0.39% below its average volume of 10532800.

Gevo’s last close was $2.65, 66.58% below its 52-week high of $7.93.

Gevo’s Sales

Gevo’s sales growth is a negative 5.2% for the ongoing quarter and 177.8% for the next. The company’s growth estimates for the present quarter is 11.1% and a drop 28.6% for the next.

Gevo’s Revenue

Year-on-year quarterly revenue growth grew by 149.5%, now sitting on 850k for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Gevo’s stock is considered to be overbought (>=80).

Gevo’s Stock Yearly Top and Bottom Value

Gevo’s stock is valued at $2.51 at 17:34 EST, way under its 52-week high of $7.93 and way higher than its 52-week low of $2.18.

Gevo’s Moving Average

Gevo’s value is way below its 50-day moving average of $2.88 and way under its 200-day moving average of $3.72.

More news about Gevo.

10. Tronox Limited Ordinary Shares (TROX) – -5.3%

Tronox Holdings plc is a vertically integrated producer of TiO2 pigment in North America and South America. It also operates in Europe, South and Central America and Africa. It operates titanium-bearing sand mining operations and is involved in beneficiation as well as smelting. The company offers TiO2 pigment, ultrafine specialty TiO2, zircon, feedstock and pig iron. It also sells titanium tetrachloride. Products manufactured by the company are used in paints and coatings as well as paper. Tronox Holdings Plc is located in Stamford (Connecticut).

NYSE ended the session with Tronox Limited Ordinary Shares falling 5.3% to $13.40 on Thursday while NYSE fell 0.82% to $14,722.03.

Volume

Today’s last reported volume for Tronox Limited Ordinary Shares is 2281140 which is 109.2% above its average volume of 1090410.

Tronox Limited Ordinary Shares’s last close was $13.40, 49.11% below its 52-week high of $26.33.

Tronox Limited Ordinary Shares’s Sales

Tronox Limited Ordinary Shares’s sales growth is 10.7% for the present quarter and 6.7% for the next.

Tronox Limited Ordinary Shares’s Revenue

Year-on-year quarterly revenue growth grew by 1.9%, now sitting on 3.66B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Tronox Limited Ordinary Shares’s stock is considered to be overbought (>=80).

Tronox Limited Ordinary Shares’s Stock Yearly Top and Bottom Value

Tronox Limited Ordinary Shares’s stock is valued at $13.40 at 17:34 EST, way under its 52-week high of $26.33 and above its 52-week low of $13.20.

Tronox Limited Ordinary Shares’s Moving Average

Tronox Limited Ordinary Shares’s worth is way under its 50-day moving average of $15.47 and way below its 200-day moving average of $19.14.

More news about Tronox Limited Ordinary Shares.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here